DUBLIN–(BUSINESS WIRE)–The “Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including Companion Dx and by Country. With Executive and Consultant Guides and COVID Pandemic Recession Forecast Revisions. 2020 to 2024” report has been added to ResearchAndMarkets.com’s offering.
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
It also includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.
A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. Learn all about it in this new report from the author. They include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.
Trends like:
- Personalized medicine
- Pharmacogenomics
- Liquid biopsy
- The emergence of new economies with large markets
- Greater understanding of the role of genetic material in Disease and Health
Working against this dynamic market are the forces of the COVID Driven Recession. The author’s latest numbers factor in the different COVID forces and their timing. And their effect on growth.
Exciting technical developments, especially in the area of pharmacogenomics, hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab.
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT
3. Market Trends.
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth.
3.2.1 Falling Prices.
3.2.2 Lower Costs
3.2.3 Testing as a Controllable Cost
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development.
3.4.1 Next Generation Sequencing
3.4.2 Shifting Role of Diagnostics
3.4.3 Multiplexing and Foundation One
3.4.4 Pharmacogenomics Technology
3.4.5 Whole Genome Sequencing
3.4.6 Gene Editing and Gene Therapy
4. Molecular Diagnostics Recent Developments
- Recent Developments – Importance and How to Use This Section
- Importance of These Developments
- How to Use This Section
- Coronavirus Pandemic Bites into European Cancer Research
- Veracyte’s Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
- Combining CRISPR and Nanopore Sequencing
- Liquid Biopsy Detects Cancer Early via Cell Clusters
- Roche, Illumina unveil 15-year cancer diagnostic tie-up
- Saga, Servier Sign Liquid Biopsy Services Deal
- Home urine test could revolutionize diagnosis of prostate cancer
5. Profiles of Key MDx Companies
6. The Global Market for MDx Cancer
6.1 MDx Cancer – Global Market Overview by Country
6.1.1 Table – Global Market by Country
6.1.2 Chart – Global Market by Country
7. Global MDx Cancer Markets – By Type of Cancer
7.1 Global Market by Cancer Type – Overview
7.2 MDx Breast Cancer
7.3 MDx Colorectal Cancer.
7.4 MDx Cervical Cancer
7.5 MDx Lung Cancer
7.6 MDx Precancer
7.7 MDx Melanoma Cancer
7.8 MDx Blood
7.9 MDx Companion Dx Development
7.10 MDx Other Cancer
8. Cancer Treatment and Trials
Companies Mentioned
- 10x Genomics, Inc
- Abbott Diagnostics
- AccuraGen Inc
- Adaptive Biotechnologies
- Aethlon Medical
- Agena Bioscience, Inc.
- Agilent
- Anchor Dx
- ANGLE plc
- ApoCell, Inc.
- ArcherDx, Inc.
- ARUP Laboratories
- Asuragen
- AVIVA Biosciences
- Baylor Miraca Genetics Laboratories
- Beckman Coulter, Inc.
- BGI Genomics Co. Ltd
- Bio-Rad Laboratories, Inc
- Bio-Reference Laboratories
- Bio-Techne
- Bioarray Genetics
- Biocartis
- Biocept, Inc
- Biodesix Inc.
- BioFluidica
- BioGenex.
- Biolidics Ltd.
- bioMrieux Diagnostics
- Bioneer Corporation.
- Bioview
- Bolidics
- Boreal Genomics
- Bristol-Myers Squibb
- Cancer Genetics
- Caris Molecular Diagnostics
- CellMax Life
- Cepheid (now Danaher)
- Charles River Laboratories
- Chronix Biomedical
- Circulogene
- Clinical Genomics
- Cynvenio.
- Cytolumina Technologies Corp.
- CytoTrack
- Datar Cancer Genetics Limited
- Diagnologix LLC
- Diasorin S.p.A.
- Enzo Life Sciences, Inc.
- Epic Sciences
- Epigenomics AG.
- Eurofins Scientific
- Exosome Diagnostics
-
And Many Many More Companies!
For more information about this report visit https://www.researchandmarkets.com/r/fhes3f
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900